Patient Characteristicsb | Death | Loss to programme | |||||||
---|---|---|---|---|---|---|---|---|---|
 |  | Crude HR 95% (CI) | P | Adjusted HR 95% (CI) | P | Crude HR 95% (CI) | P | Adjusted HR 95% (CI) | P |
Sex: (n=219) | |||||||||
Female | 99 (45.2%) | 1.0 | Â | 1.0 | Â | 1.0 | Â | 1.0 | Â |
Male | 120 (54.8%) | 1.16 (0.56 – 2.41) | 0.686 | 1.23 (0.43 – 3.51) | 0.700 | 0.94 (0.67 – 1.32) | 0.731 | 1.15 (0.68 – 1.95) | 0.600 |
Age category: (n=219) | |||||||||
< 2 years | 88 (40.2%) | 0.86 (0.38 – 1.94) | 0.712 | 1.64 (0.50 – 5.38) | 0.415 | 2.41 (1.61 – 3.61) | <0.0001 | 2.06 (1.12 – 3.83) | 0.023 |
2 – 4 years | 49 (22.4%) | 0.66 (0.24 – 1.83) | 0.429 | 0.50 (0.09 – 2.64) | 0.410 | 1.58 (0.97 – 2.58) | 0.069 | 0.95 (0.43 – 2.10) | 0.896 |
≥ 5 years | 82 (37.4%) | 1.0 |  | 1.0 |  | 1.0 |  | 1.0 |  |
WHO clinical stage: (n=174) | |||||||||
1 or 2 | 60 (34.5%) | 1.0 | Â | 1.0 | Â | 1.0 | Â | 1.0 | Â |
3 or 4 | 114 (65.5%) | 1.49 (0.63 – 3.55) | 0.367 | 2.98 (0.78 – 11.31) | 0.109 | 2.43 (1.51 – 3.90) | <0.0001 | 1.92 (1.05 – 3.53) | 0.035 |
CD4%: (n=193) | |||||||||
<15% | 148 (76.7%) | 1.69 (0.59 – 4.86) | 0.330 | 1.26 (0.39 – 4.09) | 0.700 | 0.90 (0.58 – 1.42) | 0.662 | 1.23 (0.67 – 2.26) | 0.499 |
≥15% | 45 (23.3%) | 1.0 |  | 1.0 |  | 1.0 |  | 1.0 |  |
Vital status of parent: (n=169) | |||||||||
Single orphan | 68 (40.2%) | 0.75 (026 – 2.11) | 0.582 | 0.71 (0.23 – 2.20) | 0.548 | 0.89 (0.58 – 1.38) | 0.612 | 0.90 (0.52 – 1.57) | 0.720 |
Double orphan | 16 (9.5%) | 1.93 (0.52 – 7.17) | 0.323 | 1.32 (0.30 – 5.82) | 0.711 | 0.95 (0.43 – 2.10) | 0.903 | 1.12 (0.46 – 2.70) | 0.800 |
Both alive | 85 (50.3%) | 1.0 | Â | 1.0 | Â | 1.0 | Â | 1.0 | Â |
Eligibility period: (n= 219) | |||||||||
Jun 2004 – Dec 2005 | 42 (19.2%) | 1.0 |  | 1.0 |  | 1.0 |  | 1.0 |  |
Jan 2006 – Jan 2010 | 177 (80.8%) | 1.19 (0.50 – 2.83) | 0.690 | 3.59 (0.40 – 32.4) | 0.254 | 1.86 (1.18 – 2.93) | 0.007 | 2.06 (0.86 – 4.96) | 0.106 |